Obesity and telomere status in the prognosis of patients with colorectal cancer submitted to curative intention surgical treatment

García‑Martínez,Sergio; González‑Gamo,Daniel; Fernández‑Marcelo,Tamara; Tesolato,Sofía; De La Serna,Sofía; Domínguez-Serrano,Inmaculada; Cano‑Valderrama,Oscar; Barabash,Ana; De Juan,Carmen; Torres‑García,Antonio; Iniesta,Pilar

doi:10.3892/mco.2021.2346

Obesity and telomere status in the prognosis of patients with colorectal cancer submitted to curative intention surgical treatment

Authors:
- Sergio García‑Martínez
- Daniel González‑Gamo
- Tamara Fernández‑Marcelo
- Sofía Tesolato
- Sofía De La Serna
- Inmaculada Domínguez-Serrano
- Oscar Cano‑Valderrama
- Ana Barabash
- Carmen De Juan
- Antonio Torres‑García
- Pilar Iniesta
View Affiliations

Affiliations: Department of Biochemistry and Molecular Biology, Faculty of Pharmacy, Complutense University, Madrid 28040, Spain, Digestive Surgery Service, San Carlos Hospital, Madrid 28040, Spain, Center for Biomedical Research Network on Diabetes and Associated Metabolic Diseases, San Carlos Hospital, Madrid 28040, Spain
Published online on: July 3, 2021 https://doi.org/10.3892/mco.2021.2346
Article Number: 184

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The risk of colorectal cancer (CRC) development has been associated with telomere dysfunction and obesity. However, clinical relevance of these parameters in CRC prognosis is not clear. Therefore, the aim of the present study was to evaluate the impact of obesity and telomere status in the prognosis of patients affected by CRC and submitted to curative surgical treatment. According to published data, this is the first work in which obesity and telomere status are jointly considered in relation to CRC prognosis. A prospective study including 162 patients with CRC submitted to curative surgical treatment was performed. Subjects were classified according to their BMI. Telomere status was established through telomere length and telomerase activity evaluation. Statistical analyses were performed using the SPSS software package version 22. Telomere shortening was inversely associated with BMI in patients with CRC. Notably, among patients with CRC, subjects with obesity exhibited less shortening of tumor telomeres than non‑obese patients (P=0.047). Patients with shorter telomeres, both in the tumor (median telomere length <6.5 kb) and their non‑tumor paired tissues (median telomere length <7.1 kb), had the best clinical evolution, regardless of the Dukes' stage of cancers (P=0.025, for tumor samples; P=0.003, for non‑tumor samples). Additionally, subjects with a BMI >31.85 kg/m² showed the worse clinical outcomes compared with subjects with other BMI values. Interestingly, the impact of BMI showed sex dependence, since only the group of men displayed significant differences in CRC prognosis in relation to obesity status (P=0.037). From the results of the present study, based on a multivariate prediction model to establish prognosis, it was concluded that telomere length is a useful biomarker to predict prognosis in patients with CRC. Regardless of BMI values, the improved clinical evolution was associated with shorter telomeres. The impact of BMI seems to be associated with other factors, such as sex.

View Figures

View References

1	Kolb R, Sutterwala FS and Zhang W: Obesity and cancer: Inflammation bridges the two. Curr Opin Pharmacol. 29:77–89. 2016.PubMed/NCBI View Article : Google Scholar
2	Iyengar NM, Gucalp A, Dannenberg AJ and Hudis CA: Obesity and cancer mechanisms: Tumor microenvironment and inflammation. J Clin Oncol. 34:4270–4276. 2016.PubMed/NCBI View Article : Google Scholar
3	Iyengar NM, Hudis CA and Dannenberg AJ: Obesity and cancer: Local and systemic mechanisms. Annu Rev Med. 66:297–309. 2015.PubMed/NCBI View Article : Google Scholar
4	Avgerinos KI, Spyrou N, Mantzoros CS and Dalamaga M: Obesity and cancer risk: Emerging biological mechanisms and perspectives. Metabolism. 92:121–135. 2019.PubMed/NCBI View Article : Google Scholar
5	Bhaskaran K, Douglas I, Forbes H, dos-Santos-Silva I, Leon DA and Smeeth L: Body-mass index and risk of 22 specific cancers: A population-based cohort study of 5·24 million UK adults. Lancet. 384:755–765. 2014.PubMed/NCBI View Article : Google Scholar
6	Campbell PT, Newton CC, Dehal AN, Jacobs EJ, Patel AV and Gapstur SM: Impact of body mass index on survival after colorectal cancer diagnosis: The cancer prevention study-II nutrition cohort. J Clin Oncol. 30:42–52. 2012.PubMed/NCBI View Article : Google Scholar
7	Dignam JJ, Polite BN, Yothers G, Raich P, Colangelo L, O'Connell MJ and Wolmark N: Body mass index and outcomes in patients who receive adjuvant chemotherapy for colon cancer. J Natl Cancer Inst. 98:1647–1654. 2006.PubMed/NCBI View Article : Google Scholar
8	Hanahan D and Weinberg RA: Hallmarks of cancer: The next generation. Cell. 144:646–674. 2011.PubMed/NCBI View Article : Google Scholar
9	Wu RA, Upton HE, Vogan JM and Collins K: Telomerase mechanism of telomere synthesis. Annu Rev Biochem. 86:439–460. 2017.PubMed/NCBI View Article : Google Scholar
10	Aviv A, Anderson JJ and Shay JW: Mutations, cancer and the telomere length paradox. Trends Cancer. 3:253–258. 2017.PubMed/NCBI View Article : Google Scholar
11	Luu HN, Qi M, Wang R, Adams-Haduch J, Miljkovic I, Opresko PL, Jin A, Koh WP and Yuan JM: Association between leukocyte telomere length and colorectal cancer risk in the singapore Chinese health study. Clin Transl Gastroenterol. 10:1–9. 2019.PubMed/NCBI View Article : Google Scholar
12	Cleal K, Norris K and Baird D: Telomere length dynamics and the evolution of cancer genome architecture. Int J Mol Sci. 19(482)2018.PubMed/NCBI View Article : Google Scholar
13	Tomasova K, Kroupa M, Forsti A, Vodicka P and Vodickova L: Telomere maintenance in interplay with DNA repair in pathogenesis and treatment of colorectal cancer. Mutagenesis. 35:261–271. 2020.PubMed/NCBI View Article : Google Scholar
14	Schmidt JC and Cech TR: Human telomerase: Biogenesis, trafficking, recruitment, and activation. Genes Dev. 29:1095–1105. 2015.PubMed/NCBI View Article : Google Scholar
15	Garcia-Aranda C, de Juan C, Diaz-Lopez A, Sanchez-Pernaute A, Torres AJ, Diaz-Rubio E, Balibrea JL, Benito M and Iniesta P: Correlations of telomere length, telomerase activity, and telomeric-repeat binding factor 1 expression in colorectal carcinoma. Cancer. 106:541–551. 2006.PubMed/NCBI View Article : Google Scholar
16	Fernández-Marcelo T, Sánchez-Pernaute A, Pascua I, De Juan C, Head J, Torres-García AJ and Iniesta P: Clinical relevance of telomere status and telomerase activity in colorectal cancer. PLoS One. 11(e0149626)2016.PubMed/NCBI View Article : Google Scholar
17	Maciejowski J and de Lange T: Telomeres in cancer: Tumour suppression and genome instability. Nat Rev Mol Cell Biol. 18:175–186. 2017.PubMed/NCBI View Article : Google Scholar
18	Feldser DM and Greider CW: Short telomeres limit tumor progression in vivo by inducing senescence. Cancer Cell. 11:461–469. 2007.PubMed/NCBI View Article : Google Scholar
19	Wang Y, Wang X, Flores ER, Yu J and Chang S: Dysfunctional telomeres induce p53-dependent and independent apoptosis to compromise cellular proliferation and inhibit tumor formation. Aging Cell. 15:646–660. 2016.PubMed/NCBI View Article : Google Scholar
20	Roger L, Jones RE, Heppel NH, Williams GT, Sampson JR and Baird DM: Extensive telomere erosion in the initiation of colorectal adenomas and its association with chromosomal instability. J Natl Cancer Inst. 105:1202–1211. 2013.PubMed/NCBI View Article : Google Scholar
21	Mundstock E, Sarria EE, Zatti H, Mattos Louzada F, Kich Grun L, Herbert Jones M, Guma FT, Mazzola In Memoriam J, Epifanio M, Stein RT, et al: Effect of obesity on telomere length: Systematic review and meta-analysis. Obesity (Silver Spring). 23:2165–2174. 2015.PubMed/NCBI View Article : Google Scholar
22	An R and Yan H: :Body weight status and telomere length in U.S. middle-aged and older adults. Obes Res Clin Pract. 11:51–62. 2017.PubMed/NCBI View Article : Google Scholar
23	Correia-Melo C, Hewitt G and Passos JF: Telomeres, oxidative stress and inflammatory factors: Partners in cellular senescence? Longev Healthspan. 3(1)2014.PubMed/NCBI View Article : Google Scholar
24	Masi S, Salpea KD, Li K, Parkar M, Nibali L, Donos N, Patel K, Taddei S, Deanfield JE, D'Aiuto F and Humphries SE: Oxidative stress, chronic inflammation, and telomere length in patients with periodontitis. Free Radic Biol Med. 50:730–735. 2011.PubMed/NCBI View Article : Google Scholar
25	Nikolouzakis TK, Vassilopoulou L, Fragkiadaki P, Sapsakos T, Papadakis GZ, Spandidos DA, Tsatsakis AM and Tsiaoussis J: Improving diagnosis, prognosis and prediction by using biomarkers in CRC patients. Oncol Rep. 42:2228–2244. 2018.PubMed/NCBI View Article : Google Scholar
26	Turnbull RB Jr, Kyle K, Watson FR and Spratt J: Cancer of the colon: The influence of the no-touch isolation technic on survival rates. Ann Surg. 166:420–427. 1967.PubMed/NCBI View Article : Google Scholar
27	González-Quevedo R, Iniesta P, Morán A, de Juan C, Sánchez-Pernaute A, Fernández C, Torres A, Díaz-Rubio E, Balibrea JL and Benito M: Cooperative role of telomerase activity and p16 expression in the prognosis of non-small-cell lung cancer. J Clin Oncol. 20:254–262. 2002.PubMed/NCBI View Article : Google Scholar
28	Frías C, García-Aranda C, De Juan C, Morán A, Ortega P, Gómez A, Hernando F, López-Asenjo JA, Torres AJ, Benito M and Iniesta P: Telomere shortening is associated with poor prognosis and telomerase activity correlates with DNA repair impairment in non-small cell lung cancer. Lung Cancer. 60:416–425. 2008.PubMed/NCBI View Article : Google Scholar
29	Budczies J, Klauschen F, Sinn BV, Győrffy B, Schmitt WD, Darb-Esfahani S and Denkert C: Cutoff finder: A comprehensive and straightforward Web application enabling rapid biomarker cutoff optimization. PLoS One. 7(e51862)2012.PubMed/NCBI View Article : Google Scholar
30	Bertorelle R, Rampazzo E, Pucciarelli S, Nitti D and De Rossi A: Telomeres, telomerase and colorectal cancer. World J Gastroenterol. 20:1940–1950. 2014.PubMed/NCBI View Article : Google Scholar
31	Jia H and Wang Z: Telomere length as a prognostic factor for overall survival in colorectal cancer patients. Cell Physiol Biochem. 38:122–128. 2016.PubMed/NCBI View Article : Google Scholar
32	Meyerhardt JA, Niedzwiecki D, Hollis D, Saltz LB, Mayer RJ, Nelson H, Whittom R, Hantel A, Thomas J and Fuchs CS: Cancer and Leukemia Group B 89803. Impact of body mass index and weight change after treatment on cancer recurrence and survival in patients with stage III colon cancer: Findings from cancer and leukemia group B 89803. J Clin Oncol. 26:4109–4115. 2008.PubMed/NCBI View Article : Google Scholar
33	Doleman B, Mills KT, Lim S, Zelhart MD and Gagliardi G: Body mass index and colorectal cancer prognosis: A systematic review and meta-analysis. Tech Coloproctol. 20:517–535. 2016.PubMed/NCBI View Article : Google Scholar
34	Cheung WY, Shi Q, O'Connell M, Cassidy J, Blanke CD, Kerr DJ, Meyers J, Van Cutsem E, Alberts SR, Yothers G, et al: The predictive and prognostic value of sex in early-stage colon cancer: A pooled analysis of 33,345 patients from the ACCENT database. Clin Colorectal Cancer. 12:179–187. 2013.PubMed/NCBI View Article : Google Scholar
35	Nakamura K, Furugori E, Esaki Y, Arai T, Sawabe M, Okayasu I, Fujiwara M, Kammori M, Mafune K, Kato M, et al: Correlation of telomere lengths in normal and cancers tissue in the large bowel. Cancer Lett. 158:179–184. 2000.PubMed/NCBI View Article : Google Scholar